Paradise Medspa spotlights two next-gen neuromodulators

Dr. Rebecca Weiss of Paradise Medspa says two neuromodulators in FDA review could change how aesthetic injectors plan wrinkle treatments, with one aiming for fast, short-term results and the other for longer-lasting, pre-mixed delivery. Both products may reach market in 2027, pending final FDA clearance.

Why it matters: - Two neuromodulators now in FDA review could expand how providers match treatment to patient goals. - One is designed for speed and short duration. The other is built for convenience and longer-lasting results. - The products could push aesthetic practices toward more customizable toxin treatment plans.

What happened: - Dr. Rebecca Weiss, DO, medical director of Paradise Medspa in Phoenix, gave patients and industry peers an early look at the products during a recent “Thirsty Thursday With Dr. Weiss” segment. - The preview covered Bont E, a botulinum toxin type E under development by the makers of Botox, and Relfydess, a ready-to-use formula from Galderma. - Dr. Weiss said both manufacturers have received FDA requests for additional data before moving forward. - Dr. Weiss said the products could become available as early as 2027 if they win final approval.

The details: - Bont E is a botulinum toxin type E, which differs from the Botulinum toxin type A products that currently dominate the market. - Dr. Weiss said Bont E cleaves the SNAP-25 protein at a different point than type A toxins. - Dr. Weiss said Bont E may begin working in 8 to 24 hours. - Dr. Weiss said the effect may last about two weeks. - Dr. Weiss said that profile could make Bont E useful for quick touch-ups, fast-acting results, and a low-commitment preview for patients new to neuromodulators. - Relfydess is being developed by Galderma, the company behind Dysport. - Relfydess is expected to arrive pre-mixed in solution, unlike traditional freeze-dried toxins that require reconstitution. - Dr. Weiss said the ready-mixed format could improve consistency across practices and providers. - Clinical data cited by Dr. Weiss suggests Relfydess may start working within a couple of days. - Dr. Weiss said results may last up to six months in some patients. - Dr. Weiss said Relfydess could compete with longer-duration options such as Daxxify.

Between the lines: - The two products point to a split in the market between speed and longevity. - Bont E could appeal to patients who want temporary or test-drive treatments. - Relfydess could appeal to practices that want less preparation variability and longer intervals between visits. - Dr. Weiss also used the discussion to question current reconstitution practices. - She referenced an industry lecture suggesting normal saline may preserve efficacy better than bacteriostatic saline. - Some reports cited in the segment estimate up to a 20% difference. - Paradise Medspa plans internal comparison testing on the issue. - Dr. Weiss said she is not concerned about the safety of either product, while noting the FDA’s requests appear tied to manufacturing details.

What's next: - Both products still need final FDA clearance before commercial launch. - The next milestone is additional regulatory review of manufacturing and supporting data. - Paradise Medspa plans to keep tracking reconstitution methods and may test the saline question internally. - If approved, both treatments could reach providers in 2027 and broaden patient-specific toxin choices.

The bottom line: - Neuromodulator treatments may be heading toward more tailored options, with one product built for speed and another built for duration and consistency.